Loading...
Despite the high risks for stroke and bleeding in elderly people with atrial fibrillation (AF), these patients often do not receive anticoagulation therapy. In the manufacturer-funded ELDERCARE-AF trial (NCT02801669), researchers randomized 984 patients in Japan (aged ≥80 years), who had nonvalvular AF and who were deemed not to be appropriate candidates for standard anticoagulation, to receive edoxaban (15 mg/day) or placebo. (Edoxaban is typically dosed at 60 mg/day, or at 30 mg/day in patients who have moderate or severe renal impairment, weigh ≤60 kg, or concomitantly use dronedarone, ciclosporin, erythromycin, or ketoconazole.)
About 31% of each group discontinued the trial (roughly 16% withdrew, 14% died, and 1% dropped out for other r…